Novel membrane-targeted antibiotics against drug-resistant Gram-positive bacterial infections

本项目旨在开发一种比现有治疗革兰氏阳性（G+ve）细菌感染的药物疗效更好、作用谱更广、治疗指数更高的同类最佳抗生素Vancapticin。研究小组已经确定了领先的候选药物，与几种临床比较药物相比，这些候选药物具有同等和/或更好的效力、疗效和药代动力学特征。NHMRC开发资金是为调查性新药申请选择候选药物所必需的。

This project aims to develop a best in class antibiotic, Vancapticin, with superior efficacy, broader spectra of action and improved therapeutic index than existing therapies for Gram-positive (G+ve) bacterial infections. The research team has identified lead candidates that offer equivalent &/or superior potency, efficacy & pharmacokinetic profiles compared to several clinical comparators. NHMRC Development funding is required to select a candidate for an Investigative New Drug application.